NLTX News
Archived Headlines
- US IPO Recap: Varonis provides data security for enterprises and financial security for investors 03/03/14
- 3 US IPOs planned for the week of Mar 3 03/03/14
- Anti-inflammatory biotech Aquinox Pharmaceuticals sets terms for $41 million IPO 02/28/14
- US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs 02/03/14
- Anti-inflammatory biotech Aquinox Pharmaceuticals files for a $58 million IPO 01/28/14
Bladder cancer biotech Viventia Bio files for an $86 million IPO
Viventia Bio, which is developing antibody drug conjugates for bladder and other cancers, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The Winnipeg, Canada-based company, which was founded in 1995, plans to list...read more
Autoimmune biotech Apellis Pharmaceuticals files for a $86 million IPO
Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The Crestwood, KY-based company, which was founded in...read more
US IPO Recap: Coupons.com jumps 88% and Biomet files for an IPO
Last week Coupons.com (COUP), the year's third tech IPO (after Varonis (VRNS) and Care.com (CRCM)), continued a strong run for the sector with an 88% first-day gain; the three offerings now average an 83% total return to date. Others hope to cash in on...read more
Aquinox Pharmaceuticals prices upsized IPO at $11, the midpoint of the range
Aquinox Pharmaceuticals, an early-stage biotech developing treatments for inflammation of the lung and bladder, raised $46 million by offering 4.2 million shares (upsized from 3.7 million) at $11, the midpoint of the $10 to $12 range. Aquinox...read more